Why the Distinction Changes Treatment
Reviewed by CDE Mehandi Sharma · Updated
If the treatment were the same either way, the label would be paperwork. It is not the same.
In Type 2 diabetes the core problem is that your body responds poorly to insulin. Treatment works on that resistance. In LADA the problem is that your supply of insulin is running out. Treatment has to protect what supply remains.
That difference shows up most sharply with sulfonylureas — a common, inexpensive and widely used group of tablets in India, including glimepiride, gliclazide and glibenclamide. They work by pushing your beta cells to release more insulin. In Type 2 that is reasonable. In LADA you are whipping cells that are already under attack, and studies show it leads to a faster fall in insulin production and an earlier need for injections.
In the other direction, starting insulin earlier appears to protect beta cells rather than replace them, and DPP-4 inhibitor tablets have shown promise for the same reason.
The cost of the wrong label is measurable. It is years of doses being escalated while control worsens, high blood sugar all through those years, and insulin-making capacity lost that will not come back.
This is why the diagnosis is worth pursuing even when treatment feels settled — it decides which medicines make sense.